ADC Therapeutics: 'Strong Buy' With 2 Shots On Goal For ZYNLONTA In R/R DLBCL

ADC Therapeutics remains a Strong Buy, with a major catalyst expected from topline phase 3 LOTIS-5 data for ZYNLONTA + rituximab in Q2 2026. The phase 1b LOTIS-7 study of ZYNLONTA + glofitamab showed an 89.8% overall response rate and 77.6% complete response rate, supporting the company's 2nd-line r/r DLBCL combination strategy. Additional LOTIS-7 data are expected by year-end 2026.

Analysis

The market is still underpricing how much of ADCT’s valuation is now a probability-weighted call option on the combination franchise, not the standalone asset. If the combo data continue to de-risk, the real uplift is not just higher peak sales for one label, but a materially improved negotiating position versus both regulators and future partners, because the clinical narrative shifts from salvage niche to scalable regimen-building. That matters in a small-cap biotech because the multiple expansion can arrive months before revenue inflects, especially when the next data readout sits inside a clean catalyst window.

The second-order winner is likely the payer-access and commercialization ecosystem around CD20/immune-combo regimens, while the incremental losers are other late-line DLBCL players whose differentiation is increasingly forced into tolerability rather than response rate. A high-ORR/high-CR combo also raises the bar for single-agent ADCs and less mechanistically complementary regimens; investors should expect competitive read-through pressure on names with similar post-chemo positioning. If the regimen proves durable, it could also alter sequencing assumptions, pulling some future-line demand forward into earlier-line combination use.

The key risk is not scientific plausibility, but timing and survivability. With the major readouts spread across 2026, the stock remains exposed to financing-overhang, execution drift, and the possibility that impressive early response rates fail to translate into PFS/OS or acceptable hematologic toxicity, which is what ultimately supports adoption. In other words, the next 12–18 months are about data continuity and balance-sheet confidence more than commercialization, so any gap in cadence could compress the story quickly.

Consensus may be too linear on the upside: high response rates do not automatically equal durable market share, especially in a crowded lymphoma landscape where physicians are increasingly conservative on regimen complexity. The better contrarian setup is that the current move may still be underdone if investors are only pricing one successful readout and not the option value of two shots on goal across separate combination partners. That makes ADCT more attractive as a catalyst-driven, event-dense long than as a fundamental compounder, with asymmetry skewed to the upside ahead of the 2026 data window.

Key Decisions for Investors

• Go long ADCT now into the 2026 catalyst window; size as a high-beta event position with a 6-12 month hold, targeting rerating ahead of LOTIS-5 topline. Risk/reward is attractive if the market is still discounting combo durability and label expansion optionality.
• Use call options on ADCT rather than common stock for the next 9-15 months if liquidity allows; the trade is convex to positive trial interpretation while capping downside from execution or financing noise.
• Pair long ADCT / short a basket of late-line lymphoma competitors with less compelling combination differentiation over the next 2-4 quarters; the relative trade benefits if physicians and investors migrate toward higher-ORR, combo-first narratives.
• Add on weakness only if the stock sells off on non-data-related dilution concerns; that would likely be a better entry than chasing pre-readout strength because the key upside driver is still deferred until Q2 2026.
• Tight risk control: reduce or hedge if the company signals trial cadence slippage, because the stock’s multiple likely compresses sharply if the market sees the 2026 catalyst as moving right.